Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Up 70.0% in July

Posted by Amy Steele on Jul 31st, 2026

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 263,890 shares, an increase of 70.0% from the June 30th total of 155,235 shares. Currently, 6.5% of the company’s stock are sold short. Based on an average daily trading volume, of 201,032 shares, the days-to-cover ratio is currently 1.3 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Get Our Latest Report on VBIO

Valion Bio, Inc. Common Stock Trading Down 0.7%

NASDAQ:VBIO opened at $0.28 on Friday. The stock has a market cap of $1.15 million, a price-to-earnings ratio of -0.04 and a beta of 1.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.02 and a current ratio of 3.31. The business has a fifty day moving average of $0.55 and a 200-day moving average of $0.85. Valion Bio, Inc. Common Stock has a 1 year low of $0.25 and a 1 year high of $5.60.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($2.23) earnings per share for the quarter.

Valion Bio, Inc. Common Stock Company Profile

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.